Login / Signup

Revisiting Diagnostic performances of serum erythropoïetin level and JAK2 mutation for polycythemias: analysis of a cohort of 1090 patients with red cell mass measurement.

Nabih MaslahOdonchimeg RavdanLouis DrevonEmmanuelle VergerCélia BelkhodjaChristine ChomienneBruno CassinatJean-Jacques KiladjianStéphane GiraudierMarie-Hélène Schlageter
Published in: British journal of haematology (2021)
We assessed the diagnostic performances of erythropoietin and JAK2 mutations in 1,090 patients with suspected polycythemia who were referred for red cell mass (RCM) measurement. In patients with a high haematocrit and/or haemoglobin level, a low erythropoietin level (<=3·3 mUI/ml) and JAK2 mutation showed comparable positive predictive value (PPV) for true polycythemia (RCM>=125%), 92·1% and 90% respectively. A very-low erythropoietin level (<=1·99 mUI/ml) had a PPV of 100% for polycythemia vera (PV) diagnosis. We confirmed the correlations between RCM, erythropoietin and JAK2 variant allelic frequency in PV patients. This study prompts the need to revisit the role of EPO in PV diagnostic criteria.
Keyphrases
  • recombinant human
  • single cell
  • cell therapy
  • ejection fraction
  • newly diagnosed
  • stem cells
  • prognostic factors
  • bone marrow